Since Jul 8Updated Nov 14, 2026Based on 40 AI answers from ChatGPT and Google AI Mode
Reviewed by Dimitry Apollonsky
Pear Therapeutics is mentioned in 100% of the latest answers, most often first. reSET-O is too.
ChatGPTSep 26, 2026
In the U.S., the clearest examples are:
Google AI ModeSep 26, 2026
ChatGPTSep 18, 2026
Google AI ModeSep 18, 2026
Google AI ModeSep 14, 2026
ChatGPTSep 14, 2026
Google AI ModeSep 10, 2026
ChatGPTSep 10, 2026
ChatGPTSep 6, 2026
Google AI ModeSep 6, 2026
0% of citations to these sources go to brands’ own sites.
parse.gl
Important: a billing code ≠ automatic payer reimbursement. Coverage and payment are separately determined by Medicare, Medicaid, and commercial plans.
Reimbursement for digital therapeutics (DTx) has historically relied on individual, custom value-based contracts or pilot programs with commercial payers . However, the landscape shifted when the Centers for Medicare & Medicaid Services (CMS) introduced dedicated HCPCS Level II codes for Digital Mental Health Treatment (DMHT) devices.
Rather than assigning codes to specific corporate brand names, CMS and commercial payers issue codes for categories of qualifying, FDA-cleared software-as-a-medical-device (SaMD) interventions. Companies whose FDA-cleared prescription or digital mental health treatments align with these coverage pathways benefit directly.
Under the Medicare Physician Fee Schedule, CMS established three specific codes that allow clinicians to bill for prescribing, onboarding, and managing digital mental health treatments:
The following prominent digital therapeutics companies feature FDA-cleared or authorized software products that fit into these federal and commercial reimbursement frameworks:
If you're looking into a specific product or therapeutic area (like insomnia, substance use, or musculoskeletal pain), let me know and I can detail its exact coverage status with commercial insurers like Cigna or UnitedHealthcare.
Yes. If by “achieved reimbursement codes from payers” you mean DTx companies whose products have obtained a recognized billing code and/or a payer coverage/reimbursement pathway, the U.S. landscape is still fairly small.
A key distinction: a billing code does not itself mean an insurer will pay a claim. CMS can establish a HCPCS code, while commercial payers separately decide coverage, medical necessity, benefit category, and payment.
| Company | DTx/product | Code / reimbursement pathway | Payer/reimbursement evidence |
|---|---|---|---|
| Pear Therapeutics | reSET, reSET-O, Somryst | HCPCS A9291 — FDA-cleared prescription digital behavioral therapy, per course | CMS established A9291 effective April 2022. Pear also had commercial-payer and Medicaid reimbursement arrangements, although Pear ceased operations after its 2023 bankruptcy. |
| Luminopia | Luminopia One | HCPCS A9292 — prescription digital visual therapy | Commercial payer policies recognize A9292/Luminopia; Premera's 2026 policy explicitly maps A9292 to Luminopia. |
| AppliedVR | RelieVRx | HCPCS E1905 — VR cognitive behavioral therapy device | CMS established E1905 in 2023 and subsequently assigned it a DME payment/rental pathway. This is one of the strongest examples of a DTx being incorporated into an existing Medicare benefit category. |
| Freespira | Freespira | HCPCS A9294, effective April 1, 2026 | A9294 is specifically for FDA-cleared prescription cognitive/behavioral therapy using biofeedback. Premera's 2026 policy incorporates the code. |
| Akili | EndeavorRx | Commercial payer reimbursement/coverage pathway; broader Medicare digital mental-health-treatment (DMHT) framework is relevant | EndeavorRx has been reimbursed/covered by some payers, although its current public-facing access model still includes self-pay. FDA confirms EndeavorRx as an authorized digital therapeutic for pediatric ADHD. |
| Big Health | SleepioRx / DaylightRx | Medicare G0552–G0554 DMHT pathway, subject to applicable requirements | These CMS codes created a broader Medicare billing mechanism for qualifying FDA-cleared/authorized digital mental-health-treatment devices rather than a product-specific HCPCS code. |
There are really three levels of reimbursement maturity:
The broader commercial market remains limited. An IQVIA analysis of pharmacy-dispensed PDTs found that only 58 of 211 payers (27%) receiving new PDT prescriptions had approved at least one PDT claim through May 2024; reSET-O, EndeavorRx, reSET, Luminopia, Somryst and Mahana IBS were among the products analyzed.
Bottom line: If you're looking for companies that have demonstrated that a DTx can get beyond FDA clearance into an actual payer-recognized reimbursement mechanism, the most instructive precedents are Pear, AppliedVR, Luminopia, Freespira, and Akili, with Big Health representing the newer Medicare DMHT route.
If you're evaluating this from an investment/market-map perspective, I can also give you a more comprehensive table of ~15–20 DTx companies, their FDA status, CPT/HCPCS codes, named payer contracts, covered lives, and whether reimbursement is currently active vs. merely historical.
Instead of specific companies being individually assigned unique, proprietary reimbursement codes, the digital therapeutics (DTx) industry relies on general category billing codes established by regulatory bodies like the Centers for Medicare & Medicaid Services (CMS) and the American Medical Association (AMA).
To qualify for reimbursement under these codes, a company's product must be an FDA-cleared or FDA-authorized Software as a Medical Device (SaMD) targeting specific conditions (such as depression, anxiety, insomnia, substance use disorders, or ADHD) rather than general wellness apps.
CMS finalized a dedicated framework of Level II HCPCS codes for Digital Mental Health Treatment (DMHT):
In addition, remote therapeutic monitoring (RTM) CPT codes (such as codes 98975, 98977, and 98980–98981) are used by various musculoskeletal and respiratory digital therapeutic providers to bill for patient data tracking and management.
Any company with an FDA-cleared prescription digital therapeutic (PDT) meeting the device classification criteria can utilize these payer codes when prescribed by a clinician. Prominent examples include:
Note: Commercial insurance coverage varies significantly by payer, though major entities like Cigna Healthcare have increasingly established formal coverage review criteria for qualifying prescription digital therapeutics alongside Medicare's baseline framework.
Would you like to explore how to verify coverage criteria for a specific commercial insurer or look into Remote Therapeutic Monitoring (RTM) coding requirements for a particular medical specialty?
Securing dedicated reimbursement codes (such as specific CPT or HCPCS codes) has historically been one of the biggest hurdles for the digital therapeutics (DTx) industry. While early pioneers struggled with lack of coverage—contributing to high-profile restructurings or bankruptcies like Pear Therapeutics—the reimbursement landscape shifted notably when the Centers for Medicare & Medicaid Services (CMS) introduced dedicated HCPCS Level II codes (G0552, G0553, and G0554) under the Medicare Physician Fee Schedule for Digital Mental Health Treatment (DMHT) devices.
Companies whose FDA-cleared or FDA-authorized prescription software products align with these federal reimbursement pathways, or which leverage remote therapeutic monitoring (RTM) codes, include the following:
Would you like to explore how to bill these specific G0552–G0554 codes under Medicare, or look into commercial insurance policies (like Cigna's recent coverage expansions) for digital therapeutics?
If by “achieved reimbursement codes from payers” you mean digital-therapeutics companies whose products obtained a recognized U.S. billing/reimbursement pathway and, ideally, actual payer coverage, the list is still fairly short.
A key distinction: having a CPT/HCPCS code does not automatically mean a payer will reimburse it. CMS can establish a code while commercial plans separately decide whether to cover it. IQVIA notes that early DTx codes such as A9291 and A9292 were used only minimally because they lacked national pricing and associated provider-service codes.
| Company | Product | Reimbursement code/pathway | Evidence of payer reimbursement/coverage |
|---|---|---|---|
| Pear Therapeutics | reSET, reSET-O, Somryst | HCPCS A9291 — prescription digital cognitive/behavioral therapy | Yes — strongest historical example. CMS created A9291 effective Apr. 1, 2022. Pear also had agreements with Oklahoma Medicaid and Point32Health. |
| Luminopia | Luminopia One | HCPCS A9292 — prescription digital visual therapy | Yes — increasingly clear commercial coverage. Highmark approved coverage in 2024 and Anthem Blue Cross/Blue Shield approved coverage in 2025. |
| AppliedVR | RelieVRx | HCPCS E1905 / DME pathway | Yes, but via DME rather than a pure software DTx code. This is an important example of a hardware/software DTx obtaining a more conventional Medicare reimbursement pathway. |
| WellDoc | BlueStar | CPT 99453/99454/99457 and related remote-monitoring pathway | Yes. BlueStar has historically been reimbursed through remote patient monitoring and health-plan/employer arrangements rather than a dedicated DTx HCPCS code. |
The landscape changed materially in 2025. CMS introduced three Medicare HCPCS codes specifically for digital mental health treatment (DMHT):
These are actual Medicare payment codes, although the requirements are important: the practitioner must furnish/pay for the device as part of an ongoing behavioral-health treatment plan, and G0552 is contractor-priced rather than having a single national payment rate.
This creates a new reimbursement route for products such as FDA-authorized digital treatments for behavioral health/ADHD, rather than relying exclusively on the older A9291 framework.
There are several additional companies with codes or payer-policy recognition, but I would be more cautious about calling them “successfully reimbursed”:
The important point is that FDA clearance ≠ reimbursement code ≠ payer coverage ≠ paid claims. The industry has historically struggled at each successive step. A recent review notes that even Pear had only about half of prescriptions covered by insurance, despite having the landmark A9291 code.
If you're evaluating companies from an investment, market-access, or competitive-intelligence perspective, I'd divide them this way:
Tier 1 — demonstrated payer reimbursement/coverage
Tier 2 — coding achieved, but reimbursement/coverage is less mature
The most interesting development for 2026 is probably not another company-specific code, but CMS's G0552–G0554 DMHT framework. It potentially turns Medicare into a much more standardized reimbursement channel for FDA-authorized digital mental-health treatments.
If you want, I can also build you a comprehensive table of ~20 DTx companies showing FDA product, CPT/HCPCS code, payer(s), coverage status, reimbursement amount, and whether they have actual paid claims—which is a more useful way to distinguish “has a code” from “actually gets reimbursed.”
Achieving specific reimbursement codes (such as HCPCS or CPT codes) is a major milestone for digital therapeutics (DTx) companies, though securing actual payer coverage and payment still varies widely by commercial and state Medicaid plans.
Key digital therapeutics and software-based medical device companies that have successfully driven the creation or assignment of dedicated billing and reimbursement codes include:
A9291 (Prescription digital cognitive and/or behavioral therapy, FDA-cleared, per course of treatment). This code was built to describe behavioral software solutions like Pear's reSET and reSET-O (for substance/opioid use disorder) and Somryst (for chronic insomnia). (Note: Pear underwent Chapter 11 liquidation, but its legacy coding framework paved the baseline for behavioral DTx).0740T and 0741T ) for its automated, algorithm-based insulin dose calculation, titration, and remote data storage platform.0704T–0706T ) and HCPCS code A9292 (Prescription digital visual therapy, software-only, FDA cleared, per course of treatment) for its CureSight remote amblyopia (lazy eye) eye-tracking treatment system.A9292 recognized in major commercial payer medical policies.98975–98981 ) which payers have gradually adopted for adherence and therapeutic tracking, even when product-specific codes are still rolling out.If you're working on a reimbursement strategy or market access analysis, would you like to explore:
If by “achieved reimbursement codes from payers” you mean DTx companies whose products have both (1) a recognized billing code and (2) evidence that a commercial payer/PBM actually incorporated the product into a covered/reimbursable pathway, the list is still fairly short.
| Company | DTx/product | Reimbursement code/pathway | Payer evidence | Status |
|---|---|---|---|---|
| Pear Therapeutics | reSET / reSET-O | HCPCS A9291 — prescription digital behavioral therapy, FDA-cleared, per course | Multiple commercial payers/PBMs; Pear reported 30 payers covering >31.7M lives before its bankruptcy | Strongest historical precedent |
| Luminopia | Luminopia One | HCPCS A9292 — prescription digital visual therapy | Anthem now covers Luminopia as a medical benefit; other payer policies recognize A9292 | Active |
| AppliedVR | RelieVRx | E1905 — VR cognitive behavioral therapy device | Commercial-payer coverage/reimbursement pathways; Premera specifically identifies E1905 for RelieVRx | Active/established |
| Freespira | Freespira | Payer-specific contracting/benefit pathways; newer A9294 is relevant to biofeedback DTx | Highmark and other payer relationships; coverage is generally plan-specific | Active |
| d-Nav / Insulia-type diabetes DTx | Diabetes-management software | CPT 0740T/0741T and related pathways | Payer policies have incorporated these codes/products | Active, but different coding model |
CMS created A9291 specifically for prescription digital behavioral therapy and made it effective April 1, 2022. Importantly, CMS said the purpose included facilitating access for non-Medicare payers; creation of the code itself did not establish Medicare payment.
Luminopia followed with A9292, effective October 1, 2023. CMS explicitly established the code for Luminopia but assigned no Medicare payment at the time. Commercial reimbursement is a different question: Anthem now states that Luminopia is covered as a medical benefit for eligible members.
There are really three levels of “reimbursement success” in DTx:
Those are not equivalent. For example, Aetna's current policy lists numerous DTx products—including EndeavorRx, Freespira, Luminopia One, NightWare, RelieVRx, reSET/reSET-O and others—but being listed in a payer policy does not necessarily mean every listed product is covered; the policy distinguishes covered products, noncovered products and products requiring specific criteria.
There is now another dedicated DTx code:
A9294 — “Prescription digital cognitive and/or behavioral therapy, biofeedback, FDA cleared, per course of treatment,” effective April 1, 2026.
Premera's 2026 policy incorporates A9294, while its policy also specifically maps A9291 to reSET/reSET-O and A9292 to Luminopia.
Separately, CMS expanded Remote Therapeutic Monitoring (RTM) in 2026 with codes 98979, 98984 and 98985, explicitly including “digital therapeutic intervention” in the code descriptors. This creates a reimbursement route that doesn't require a DTx-specific HCPCS code.
If you're looking for companies that have demonstrated actual payer reimbursement rather than merely FDA clearance, I'd put them roughly into these buckets:
One particularly interesting point is that “getting a code” is no longer necessarily the key milestone. The 2026 RTM expansion means a DTx company can potentially obtain reimbursement through an existing clinical-service pathway, while dedicated HCPCS codes such as A9291/A9292/A9294 provide a more explicit product-level mechanism.
If you're evaluating this for investment or competitive intelligence, I can build a 2026 table of ~20 DTx companies with FDA status, HCPCS/CPT code, named payer, covered lives, Medicare/Medicaid status, and whether there is evidence of actual paid claims. That would give a much clearer picture of who has truly cracked reimbursement versus who merely has a billing code.
Yes. But there’s an important distinction: a reimbursement code is not the same thing as payer coverage. CMS/AMA establish billing codes; commercial insurers and Medicaid plans decide whether to cover and pay them.
As of 2026, the U.S. digital-therapeutics companies with the strongest evidence of having achieved a payer-recognized reimbursement pathway include:
| Company | Product | Code / pathway | Payer status |
|---|---|---|---|
| Pear Therapeutics | reSET, reSET-O, Somryst | A9291 | Strong historical precedent; commercial and Medicaid coverage existed, but Pear ceased operations in 2023 |
| Luminopia | Luminopia One | A9292 | Dedicated HCPCS code and payer policies recognizing the product |
| AppliedVR | RelieVRx | E1905 | DME/VR reimbursement pathway; recognized by commercial payer policies |
| Freespira | Freespira | A9294 | New dedicated HCPCS code effective Apr. 1, 2026; payer policies are beginning to incorporate it |
| Big Health | SleepioRx, DaylightRx | G0552–G0554 | Medicare DMHT pathway beginning 2025 |
| Akili / EndeavorRx | EndeavorRx | G0552–G0554 | Medicare DMHT pathway expanded in 2026 to include ADHD devices |
| Otsuka / Click Therapeutics | Rejoyn | G0552–G0554 | Potentially within the Medicare DMHT pathway, subject to the device/service and coverage requirements |
1. Pear Therapeutics — the original benchmark
Pear's reSET/reSET-O products were the catalyst for HCPCS A9291, created in 2022 for FDA-cleared prescription digital cognitive/behavioral therapy. CMS explicitly discussed the lack of coding infrastructure as an access problem.
There was actual payer adoption: for example, SelectHealth added reSET-O as a covered benefit for certain commercial members, and payer surveys identified reSET and reSET-O among the most frequently covered PDTs.
The caveat is that Pear went bankrupt in 2023, so I would classify this as a successful reimbursement precedent, not a current commercial success.
2. Luminopia — one of the clearest surviving code + payer examples
Luminopia One has its own HCPCS code, A9292, for prescription digital visual therapy. Premera's current policy specifically identifies A9292 for Luminopia, while other Blue Cross policies have incorporated Luminopia into their covered/authorized DTx frameworks.
3. AppliedVR — successful device/DME route
RelieVRx is interesting because it demonstrates an alternative to the pure-software DTx model. Payers such as Premera recognize E1905, the VR cognitive-behavioral-therapy device code, for RelieVRx.
4. Freespira — the newest product-specific code
A significant 2026 development is A9294, created for FDA-cleared prescription digital cognitive/behavioral therapy using biofeedback. The code became effective April 1, 2026. Current payer policies identify Freespira under A9294.
The most important change for the industry is arguably G0552, G0553 and G0554, introduced January 1, 2025:
CMS created these specifically for FDA-cleared/authorized digital mental-health-treatment devices used alongside ongoing behavioral-health treatment.
And in 2026, CMS expanded the policy to cover qualifying digital devices for ADHD, which is particularly relevant to EndeavorRx/Akili.
I would not put companies such as Omada, Hinge Health, Sword Health, Virta, etc. in the same category if your question is specifically about a DTx obtaining a dedicated reimbursement code. They have substantial payer/employer reimbursement, but largely through conventional medical services, value-based contracts, employer benefits, RTM, or other existing mechanisms rather than a dedicated prescription-DTx HCPCS code.
That's an important distinction if you're doing a competitive landscape or evaluating "who has actually solved reimbursement?"
Also, having a code doesn't mean broad payment: IQVIA notes that the early A9291/A9292 codes had no national pricing and were used relatively minimally, while current payer policies can still make coverage plan-specific.
Bottom line: if you're looking for the strongest U.S. reimbursement precedents, I'd rank Pear (historical), Luminopia, AppliedVR, and Freespira as the clearest examples of product-specific coding + payer recognition, while Big Health and Akili are especially important examples of the newer Medicare G-code pathway.
If you'd like, I can also build a company-by-company table of 15–25 DTx companies showing FDA clearance, CPT/HCPCS code, specific payer coverage (United, Cigna, Aetna, BCBS, Medicaid, Medicare), reimbursement amount, and whether reimbursement is currently active in 2026.
Unlike traditional pharmaceuticals or hardware medical devices, digital therapeutics (DTx) have historically faced a unique reimbursement bottleneck. Rather than receiving product-specific billing codes, DTx products have relied heavily on general service-based codes (such as Remote Therapeutic Monitoring [RTM] CPT codes 98975–98981 ) or specific macro-level HCPCS codes created by the Centers for Medicare & Medicaid Services (CMS).
The regulatory and payment landscape centers around structural code categories rather than individual corporate branding, though several pioneering companies have successfully aligned their FDA-cleared software with these active reimbursement pathways:
Instead of dedicated permanent product codes for every brand, CMS established overarching framework codes that clinicians use to bill for patient onboarding, data review, and monthly management of software-driven therapies:
98975, 98977, 98980): Cover musculoskeletal and respiratory data tracking. Companies offering digital physical therapy, joint rehabilitation, or remote chronic disease management (such as Hinge Health or K ماهی/Kare -adjacent musculoskeletal apps) have aligned their platforms with these codes so providers can bill for clinician-led oversight.G0552, G0553, G0554): Implemented via the Medicare Physician Fee Schedule to reimburse mental/behavioral health digital devices and treatment plans. This opened avenues for prescription and clinical mental health apps.A9291 (Prescription digital behavioral therapy, FDA cleared, per course of treatment ) for products like reSET® and reSET-O® . Although Pear subsequently underwent Chapter 11 restructuring, their market groundwork defined how prescription digital therapeutics (PDTs) map onto payer systems.The Current Reality
As highlighted by the Digital Therapeutics Alliance (DTA), rather than individual companies holding exclusive "reimbursement codes," the industry operates via shared general CPT/HCPCS frameworks . Clinicians utilize established RTM or DMHT administrative codes to get paid for monitoring patient data and engagement inside an FDA-cleared software platform.
If you're evaluating a specific product, let me know:
I can dig deeper into their current market access strategy or clinical reimbursement status.